13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
36 檔
22.6%
In Q4 2024, Prosight Management, LP's U.S. equity holdings reached a combined market value of $580.4M, distributed across 36 disclosed stock positions.
In Q4 2024, Prosight Management, LP adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 17 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 7.79% | +2.93% | -0.37% | |
| 2 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 7.58% | — | +12113.20% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 7.55% | — | -8.45% | |
| 4 | MGTX | MeiraGTx Holdings plc | Stock-Other | 7.39% | -3.52% | -10.40% | |
| 5 | ABCL | Abcellera Biologics Inc | Stock-Other | 5.95% | — | -19.05% | |
| 6 | ✓ | Adc Therapeutics SA | Stock-Other | 5.23% | -3.66% | -1.26% | |
| 7 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.16% | — | -3.16% | |
| 8 | ICLR | ICON Public Limited Company | Stock-Healthcare | 4.93% | — | — | |
| 9 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.90% | -0.82% | EXIT | |
| 10 | JANX | Janux Therapeutics Inc | Stock-Other | 4.88% | +1.98% | +60.86% | |
| 11 | SDGR | Schrodinger Inc | Stock-Other | 3.84% | -0.95% | EXIT | |
| 12 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 3.78% | +0.01% | +583.14% | |
| 13 | ZYME | Zymeworks Inc | Stock-Other | 3.32% | +0.83% | -10.64% | |
| 14 | KURA | Kura Oncology Inc | Stock-Other | 3.19% | -0.66% | +87.91% | |
| 15 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.40% | — | — | |
| 16 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 2.34% | — | -51.69% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.27% | +1.57% | +11.89% | |
| 18 | STTK | Shattuck Labs Inc | Stock-Other | 2.22% | +1.84% | +16.91% | |
| 19 | IMVT | Immunovant Inc | Stock-Other | 2.09% | -0.72% | EXIT | |
| 20 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.62% | — | +42.25% | |
| 21 | PRTA | Prothena Corporation plc | Stock-Other | 1.60% | — | -13.52% | |
| 22 | ✓ | Galapagos NV | Stock-Other | 1.34% | — | — | |
| 23 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.11% | — | +29.21% | |
| 24 | HAE | Haemonetics Corp/mass | Stock-Other | 1.01% | — | -28.15% | |
| 25 | CNC | Centene CORP | Stock-Healthcare | 0.92% | — | — | |
| 26 | SGHT | Sight Sciences Inc | Stock-Other | 0.91% | — | +71.09% | |
| 27 | LIVN | LivaNova PLC | Stock-Other | 0.90% | — | -22.22% | |
| 28 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.88% | -0.02% | +107.69% | |
| 29 | ERAS | Erasca Inc | Stock-Other | 0.66% | — | -52.26% | |
| 30 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.51% | — | — | |
| 31 | CDNA | Caredx Inc | Stock-Other | 0.47% | — | — | |
| 32 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.42% | — | -18.19% | |
| 33 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 0.28% | — | — | |
| 34 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.26% | +0.11% | +8.82% | |
| 35 | IMNM | Immunome Inc | Stock-Other | 0.16% | — | +38.86% | |
| 36 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.15% | -0.69% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACHC | Acadia Healthcare Co Inc | +7.5% | +12113.20% | Add |
| 2 | ICLR | ICON Public Limited Company | +4.9% | NEW | New buy |
| 3 | RCKT | Rocket Pharmaceuticals Inc | +3.1% | +583.14% | Add |
| 4 | JANX | Janux Therapeutics Inc | +2.6% | +60.86% | Add |
| 5 | AM6 | Amicus Therapeutics Inc | +2.4% | NEW | New buy |
| 6 | MGTX | MeiraGTx Holdings plc | +2.4% | -10.40% | Trim |
| 7 | ✓ | Galapagos NV | +1.3% | NEW | New buy |
| 8 | CNC | Centene CORP | +0.9% | NEW | New buy |
| 9 | BBIO | Bridgebio Pharma Inc | +0.7% | -8.45% | Trim |
| 10 | MIRM | Mirum Pharmaceuticals Inc | +0.7% | -3.16% | Trim |
| 11 | SDGR | Schrodinger Inc | +0.6% | +2.93% | Add |
| 12 | 2655787D | Blueprint Medicines CORP | +0.6% | +42.25% | Add |
| 13 | SYRE | Spyre Therapeutics Inc | +0.5% | NEW | New buy |
| 14 | LKFT | Lakefront Biotherapeutic-adr | +0.5% | -0.37% | Trim |
| 15 | ZYME | Zymeworks Inc | +0.5% | -10.64% | Trim |
| 16 | CDNA | Caredx Inc | +0.5% | NEW | New buy |
| 17 | FTRE | Fortrea Holdings Inc | +0.3% | NEW | New buy |
| 18 | CTMX | Cytomx Therapeutics Inc | +0.2% | +29.21% | Add |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | +107.69% | Add |
| 20 | OKUR | Onkure Therapeutics Inc-a | +0.2% | NEW | New buy |
| 21 | ABCL | Abcellera Biologics Inc | +0.1% | -19.05% | Trim |
| 22 | SGHT | Sight Sciences Inc | +0.1% | +71.09% | Add |
| 23 | IMNM | Immunome Inc | 0% | +38.86% | Add |
| 24 | ROIV | Roivant Sciences Ltd. | 0% | -12.87% | Trim |
| 25 | ✓ | Mural Oncology Pub LTD Co | 0% | -18.19% | Trim |
| 26 | RNTX | Rein Therapeutics Inc | -0.1% | +8.82% | Add |
| 27 | ✓ | Shattuck Labs Inc | -0.1% | EXIT | Sold out |
| 28 | IMRX | Immuneering CORP - Class A | -0.1% | EXIT | Sold out |
| 29 | KURA | Kura Oncology Inc | -0.2% | +87.91% | Add |
| 30 | OVID | Ovid Therapeutics Inc | -0.2% | EXIT | Sold out |
| 31 | SEM | Select Medical Holdings CORP | -0.2% | EXIT | Sold out |
| 32 | ✓ | Corvel CORP | -0.2% | EXIT | Sold out |
| 33 | LIVN | LivaNova PLC | -0.3% | -22.22% | Trim |
| 34 | HAE | Haemonetics Corp/mass | -0.3% | -28.15% | Trim |
| 35 | SNDX | Syndax Pharmaceuticals Inc | -0.4% | +11.89% | Add |
| 36 | PRTA | Prothena Corporation plc | -0.4% | -13.52% | Trim |
| 37 | ✓ | Vincerx Pharma Inc | -0.4% | EXIT | Sold out |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | -0.4% | EXIT | Sold out |
| 39 | IMVT | Immunovant Inc | -0.5% | -17.43% | Trim |
| 40 | ERAS | Erasca Inc | -0.7% | -52.26% | Trim |
| 41 | VKTX | Viking Therapeutics Inc | -0.8% | EXIT | Sold out |
| 42 | TECX | Tectonic Therapeutic Inc | -1% | EXIT | Sold out |
| 43 | ✓ | Cassava Sciences Inc | -1.1% | EXIT | Sold out |
| 44 | COGT | Cogent Biosciences Inc | -1.1% | EXIT | Sold out |
| 45 | ✓ | Ishares Tr | -1.6% | EXIT | Sold out |
| 46 | NBIX | Neurocrine Biosciences Inc | -1.8% | EXIT | Sold out |
| 47 | ZBH | Zimmer Biomet Holdings Inc | -2.1% | -51.69% | Trim |
| 48 | ✓ | Adc Therapeutics SA | -2.2% | -1.26% | Trim |
| 49 | CYTK | Cytokinetics Inc | -2.5% | EXIT | Sold out |
| 50 | DXCM | Dexcom Inc | -2.6% | EXIT | Sold out |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 36 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LKFT, ACHC, BBIO) accounted for 22.6% of total reported equity market value during Q4 2024.
Top New Position Initiated
ICLR
市值: $17.8M
Top Position Liquidated / Trimmed
MCK
前期市值: $17.7M
During Q4 2024, Prosight Management, LP's top holdings by market value included LKFT (7.8%)、ACHC (7.6%)、BBIO (7.5%). The largest single position, LKFT, represented 7.8% of total portfolio value.
In Q4 2024, Prosight Management, LP made 53 total portfolio adjustments, initiating 8 new buys, adding to 13 positions, trimming 15 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.